Cannabis Science Inc (OTCMKTS:CBIS) continues to search for support, and recent action certainly makes a case that the stock may have carved out a foothold around the nickel/share level after dropping around 55% of its value since poking up through the $0.13 level in February. The company’s most recent catalyst is its own new “Growth Guidance Report”. For the already-cynical, this is desperate stuff, with adjectives and adverbs in place of numbers and news. That said, the stock is showing some support and we have seen this thing launch several times in the past. So, shorts beware.
According to the release, “the Company has already achieved a good number of its goals for 2017. The Growth Guidance Report has CBIS outlined as an industry leader. Cannabis Science is aggressively expanding its corporate footprint in legal states throughout the USA, to help self-medicating patients with multiple critical ailments.”
Cannabis Science Inc (OTCMKTS:CBIS) has been down an interesting road over recent months. We see the company as actively striving for, and achieving a bump in legitimacy through some of its newly established relationships.
The company defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug.
In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As we noted above, those already skeptically inclined toward CBIS – with its long history of dilution and total lack of revenue growth – will find the company’s communications almost comical. But, those burned by bets on the death spiral know all too well how this one can impale overly bold shorts.
“I am particularly excited about the Cannabis Science Consortium. This consortium, led by CBIS, will include collaborations with research and patient-care institutions in the U.S. and worldwide. Our Consortium provides CBIS with a global platform to develop cannabinoid-based medicines and to undertake clinical trials for several medicines that have the potential to help so many people. By partnering with leading individuals and institutions, we hope to increase the cannabinoid-based medicines in our development pipeline, and shorten the release time. CBIS, Inc. is working in three major areas: more efficient and effective delivery of cannabinoids to the sites of disease; understanding how to create the right mixtures of cannabinoids; and defining the diseases that may benefit from cannabinoid therapeutics. In these endeavors we are informed by the 2016 National Academies of Sciences, Engineering, and Medicine Report on ‘The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research’,” stated Cannabis Science Inc., Dr. Allen Herman, Chief Medical Officer (CMO).
Recent action has seen 4% added to share values of the name over the past week of action, but this action is running counter to the larger trend in the name. This is emblematic of the stock. CBIS has a history of dramatic rallies. Furthermore, the listing has witnessed a pop in interest, as transaction volume levels have recently pushed 13% above the average volume levels in play in this stock over the longer term.
Currently trading at a market capitalization of $127M, CBIS has a bankroll ($333K) of cash on the books, which stands against about $2M in total current liabilities. CBIS is pulling in trailing 12-month revenues of $9K. However, the company is seeing declines on the top line on a quarterly y/y basis, with revenues falling at -98.1%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!